ascendis pharma glp-1 Novo Nordisk, Ink $285M Pact Ascendis and Novo Nordisk sign

Janoshik approved, COA included.

Employers can't shirk responsibility for novel weight loss drugs forever, executives argued at a recent Newsweek event.

As more adults compare online GLP-1 weight loss programs in 2026, this Shed GLP-1 review explores how the telehealth platform is positioned for provider-guided care access, what patients should know about compounded and FDA-approved options, and which pricing, eligibility, and guarantee factors may influence the experience.

The Tirzepatide Oral Protocol from PlexusDx is a compounded GIP/GLP-1 dual agonist prescribed by licensed providers

Learn which body contouring procedures best support patients after semaglutide or GLP-1 treatment and how to address common post-weight loss concerns.

The percentage of Americans taking GLP-1 drugs such as Ozempic or Zepbound to lose weight has nearly quadrupled since 2024, according to a new survey by Gallup